We queried the Memorial Sloan Kettering integrated mutation profiling of actionable cancer targets (MSK-IMPACT) Clinical Sequencing Cohort database, which contained data on the time to clinical progression on first-line erlotinib therapy for 11 patients whose tumors contained co-occurring EGFR activating/erlotinib sensitizing mutations and ATM mutations (Table S2). This evidence concerns the gene ATM and cancer.